报价延迟最少15分钟:2025/11/15 21:09 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7532 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.79/-0.69
|
|
企业价值
81.93M
|
| 资产负债 |
|
每股账面净值
0.82
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
235.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/15 21:09 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause tofibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
